A nationwide cohort study suggests clarithromycin-based therapy for Helicobacter pylori eradication is safe in patients with stable coronary heart disease and subsequent peptic ulcer disease

Table 3 Adjusted hazard ratio (HR) of study outcomes associated with cumulative define daily dose (cDDD) of clarithromycin

Take nonusers as the reference	Overall mortality			Cardiovascular mortality			Cardiovascular morbidity
Take nonusers as the reference	Events (n, %)	Adjusted HR* (95% CI)	p value	Events (n, %)	Adjusted HR* (95% CI)	p value	Events (n, %)	Adjusted HR^# (95% CI)	p value
cDDD of clarithromycin
≦ 1000	25 (12.8)	1.68 (0.88–3.22)	0.12	1 (0.5)	Not converged	NA	12 (6.2)	1.00 (0.43–2.32)	0.99
> 1000–3000	66 (10.8)	2.33 (1.53–3.56)	< 0.0001	7 (1.1)	5.06 (0.78–32.74)	0.09	44 (7.2)	1.42 (0.87–2.32)	0.16
> 3000–5000	217 (9.2)	0.97 (0.81–1.17)	0.74	16 (0.7)	0.79 (0.41–1.54)	0.49	211 (9.0)	0.91 (0.75–1.10)	0.32
> 5000	87 (9.5)	0.89 (0.66–1.19)	0.42	4 (0.4)	0.63 (0.17–2.41)	0.50	74 (8.1)	0.83 (0.61–1.15)	0.27

HR hazard ratio, CI confidence interval
*Adjusted for all covariates (age per year, sex, comorbidity, Charlson comorbidity index, number of medical visits, and drugs use) listed in Table 1
^#Adjusted for all covariates (age per year, sex, comorbidity, Charlson comorbidity index, number of medical visits, and drugs use) listed in Table 1 and competing mortality

ISSN: 1471-230X